PL EN


Preferences help
enabled [disable] Abstract
Number of results
2016 | 50 | 250-265
Article title

Use of apheresis in the treatment of Haematological conditions

Content
Title variants
Languages of publication
EN
Abstracts
EN
Apheresis is a medical technology in which the blood of an individual is passed through an apparatus that separates out one particular blood component and returns the remainder into circulation. In this review, five types of apheresis procedures were studied, which were Erythrocytapheresis, Leucocytapheresis, Plasmapheresis, Photopheresis and Plateletpheresis. The aim of this review was to present the efficacy, safety and use of apheresis procedures in the treatment of diseases associated with abnormal blood components. Erythrocytapheresisis used for blood donations and treatment of different diseases such as Polycythemia vera and severe cases of Sickle Cell Anaemia. Leukapheresis is used for separation of white blood cells and also in disease conditions such as Ulcerative colitis. Plasmapheresis is used for separating plasma from whole blood for use in the manufacture of various medications. It is also performed to remove life-threatening antibodies in the blood like in cases of Thrombotic Thrombocytopenic Purpura and Multiple Sclerosis. Photopheresis is mainly used as an immunosuppression therapy in cases of acute and chronic graft-versus-host-disease, cutaneous T-cell Lymphoma and cutaneous Lupus Erythematosus. Plateletpheresis is used to remove platelets from the body of patients or donors for future use. Apheresis enhances the correct use of blood and blood components. It can be a valuable and safe initial treatment for a number of ailments resulting from blood component abnormalities and patients should be brought to light about these procedures before other treatment methods are introduced.
Year
Volume
50
Pages
250-265
Physical description
Contributors
author
  • Department of Medical Lab. Science, Haematology Unit, College of Medical Sciences University of Calabar, Calabar, Nigeria, okaforifymaryann@yahoo.com
  • Department of Medical Lab. Science, Haematology Unit, College of Medical Sciences University of Calabar, Calabar, Nigeria, okaforifymaryann@yahoo.com
References
  • [1] Alvara, P. and Eleftherios, V. (1997). Applications of Therapeutic Apheresis in Patients with Malignant Disease. The Oncologist 2: 94-103.
  • [2] Batocchi, A. P., Evoli, A., Di Schino, C and Tonali, P. (2000). "Therapeutic apheresis in myasthenia gravis". Therapeutic apheresis:official journal of the International Society for Apheresis and the Japanese Society for Apheresis, 4: 275-279.
  • [3] Crovetti, G., Carabelli, A., Berti, E., Guizzardi,M., Fossati,S., De Filippo,C. and Bertani, E. (2000). Photopheresis in cutaneous T-cell lymphoma: five-year experience. International Journal of Artificial Organs. 23: 55-62.
  • [4] Dettke, M., Hlousek, M. and Kurz, M. (1998). Increase in endogenous thrombopoietin in healthy donors after automated plateletpheresis. Transfusion. 38: 449-453.
  • [5] Diehl A, Frey G. (1998). Optimization of a Blood Separation Process Based on Simulation. Proceedings of the IEE International Conference on Simulation. pp. 19-26.
  • [6] Drew, MJ (2002). "Plasmapheresis in the dysproteinemias". Therapeutic apheresis: official journal of the International Society for Apheresis and the Japanese Society for Apheresis, 6: 45-52.
  • [7] Edelson R, Berger C, Gasparro F. (1987). Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. England Journal of Medicine, 316: 297-303.
  • [8] Eureka Strategic Report (2007). Joint Study on Appropriate use of Blood and blood Products.
  • [9] Flowers M. E, Apperley J. F. and van Besien, K. (2008). A multi-center prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 112: 2667-2674.
  • [10] Foss F. M, DiVenuti G. M and Chin K (2005). Prospective study of extracorporeal photopheresis in steroid-refractory or steroidresistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant. 35: 1187-1193.
  • [11] Greinix HT, Knobler RM, Worel N. (2006). The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica. 91:405-408.
  • [12] Grima, K.M. (2000). Therapeutic apheresis in hematological and oncological diseases. Journal of Clinical Apheresis 15: 28-52.
  • [13] Kanold J, Merlin E, Halle P. (2007). Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion. 47: 2276-2289.
  • [14] Khatri, B. O, McQuillen, M. P., Harrington, G. J., Schmoll, D. and Hoffmann, R. G. (1985). Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology, 35: 312-319.
  • [15] Kim, H. C., Dugan, N. P., Silber, J. H., Martin, M. B., Schwartz, E., Ohene-Frempong K., and Cohen, A. R. (1994). Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood. 83: 1136-114.
  • [16] Koch, H. M., Bolt, H. M., Preuss, R., Eckstein, R., Weisbach, V. and Angerer, J. (2005). "Intravenous exposure to di(2-ethylhexyl)phthalate (DEHP): Metabolites of DEHP in urine after a voluntary platelet donation". Archives of Toxicology 79: 689-693.
  • [17] Koch, H. M., Angerer, J., Drexler, H., Eckstein, R. and Weisbach, V. (2005). "Di(2-ethylhexyl)phthalate (DEHP) exposure of voluntary plasma and platelet donors". International Journal of Hygiene and Environmental Health. 208 : 489-498.
  • [18] Loftus, E. V. (2004). Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 126:1504-1517.
  • [19] Marques, M. B., Tuncer, H. H. (2006). Photopheresis in solid organ transplant rejection. Journal of Clinical Apheresis. 21:72-77.
  • [20] McMaster, P. and Shann, F. (2003). The use of extracorporeal techniques to remove humoral factors in sepsis. Pediatric Critical Care Medicine. 4: 2-7.
  • [21] Mori, M., Kuwabara, S., Fukutake, T. and Hattori, T. (2002). "Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases". Journal of neurology, neurosurgery, and psychiatry, 72: 680.
  • [22] Morruzzi, C., Liu, V., Bohbot, A., Cribier, B. and Lipsker, D. (2009). Four cases of photopheresis treatment for cutaneous lupus erythematosus refractory to standard therapy. Annual Journal of Dermatology and Venereology. 136: 861-867.
  • [23] Newsom-Davis J, Murray NMF (1984). Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 34: 480-485.
  • [24] Okafor, C., Ward, D. M., Mokrzycki, M. H., Weinstein, R., Clark, P. and Balogun, R. A. (2010). Introduction and overview of therapeutic apheresis. Journal of Clinical Apheresis, 25: 240-249.
  • [25] Oxelmark, L., Hillerås, P., Dignass, A., Mössner, J., Schreiber, S. and Kruis, W. (2007). Quality of life in patients with active ulcerative colitis treated with selective leukocyte apheresis. Scand Journal of Gastroenterology. 42: 406-407.
  • [26] Papadarkis, K. A., and Targan, S. R. (2005). Role of cytokines in the pathogenesis of inflammatory bowel disease. Annual Review of Medicine. 4: 1289-1298.
  • [27] Pavletic, S. Z., Martin, P., and Lee, S. J. ( 2006). Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biology of Blood Marrow Transplant.12: 252-266.
  • [28] Present, D. H. ( 2006). How to do without steroids in inflammatory bowel disease. Inflammatory Bowel Disease. 45: 48-57.
  • [29] Rodnitzky, R. L. and Goeken, J. A. (1999). Complications of plasma exchange in neurological patients. Archives of Neurology; 39:350-353.
  • [30] Rodriguez, M., Karnes, W. E., Bartleson, J. D. and Pineda, A. A. (1993). Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 43: 1100-1104.
  • [31] Rydberg, L. (2001). ABO-incompatibility in solid organ transplantation. Transfusion Medicine, 11:325-342.
  • [32] Schneider, M. (2000). Plasmapheresis: Indications and Techniques. Saudi Journal of Kidney Disease and Transplant. 11: 315-324.
  • [33] Schwella, N., Braun, A., Ahrens, N., Rick, O. and Salama, A. (2003). Leukapheresis after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: a novel approach to harvest a second autograft.
  • [34] Simon, T. L., Dzik, W. H. and Snyder, E. L. (2002). Rossi’s principles of transfusion medicine. Lippincott Williams and Wilkins, Philadepia. Pp. 212-214.
  • [35] Siti Nadiah, A. K., Nor Asiah, M., Nur Syimah, A. T., Normi, M., Nor Aini, A., Mohd, Z., Shahnaz, M., Faraizah, A. K. and Faisal, M. A. (2013). Effects of plateletpheresis on blood coagulation parameters in healthy donors at National Blood Centre, Kuala Lumpur, Malaysia. Transfusion and apheresis science, 49: 507-510.
  • [36] Sloan, C., Youngblood, M. D., Yi Deng, M. D., Alice Chen, M. D., Charles, D. and Collard, M. D. (2013). Perioperative Therapeutic Plasmapheresis. Anesthesiology 3: 722-728.
  • [37] Smith, J. W., Weinstein, R. and Hillyer, K. I. (2003). Therapeutic apheresis: A summary of current indication categories endorsed by the AABB and American Society for Apheresis. Transfusion 43: 820-822.
  • [38] Suchin, K. R., Cassin, M. and Washko, R. (1999). Extracorporeal photochemotherapy does not suppress T- or B-cell responses to novel or recall antigens. Journal of Academic Dermatology. 41: 980-986.
  • [39] Szczepiorkowski, Z. M., Winters, J. L., Bandarenko, N., Kim, H. C., Linenberger, M. L., Marques, M. B., Sarode, R. and Schwartz, J. (2010). "Guidelines on the use of therapeutic apheresis in clinical practice-Evidence-based approach from the apheresis applications committee of the American Society for Apheresis". Journal of Clinical Apheresis 25: 83-177.
  • [40] Tibble, J. A., Sigthorsson, G., Bridger, S., Fagerhol, M. K., Bjarnason, I. (2000). Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 119: 15-22.
  • [41] Ullrich, H., Fischen, R., Grosse, R., Kordes, U., Schubert, C., Altstadt, B. and Andreu, G. (1998). Erythrocytapheresis: Do Not Forget a Useful Therapy! Transfusion Medicine and Hemotherapy, 35: 25-30.
  • [42] Valbonesi, M. and Bruni, R. (2000). Clinical application of therapeutic erythrocytapheresis (TEA). Transfusion Science, 22: 183-194.
  • [43] Wallace, D. J. (1999). "Apheresis for lupus erythematosus". Lupus 8, 174-180.
  • [44] Welsby, I. J., Um, J., Milano, C. A., Ortel, T. L. and Arepally G. (2010). Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesthesiology and Analgesics. 110: 30.
  • [45] WHO 2001. The WHO Handbook on the Clinical Use of Blood (2001).
  • [46] WHO 2015. Blood transfusion safety: Safe and rational clinical use of blood.
  • [47] Wu, A., Buhler, L. H. and Cooper, D. K. (2003). ABO-incompatible organ and bone marrow transplantation: Current status. Transplantation International 16:291-299
  • [48] Yazdi, M. F., Baghianimoghadam, M., Nazmiyeh, H., Ahmadabadi, A. D. and Adabi, M. A. (2012). "Response to plasmapheresis in myasthenia gravis patients: 22 cases report". Romanian journal of internal medicine, 50: 245-247.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-ed56263f-e88d-4924-9ca8-f8245bfd45c8
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.